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TO THE EDITOR: I read with great interest the recently published
study by Janmaat et al,1 who reported on biologic and clinical factors
associated with gefitinib therapy outcome in advanced esophageal
cancer.Within a panel of candidate predictivemarkers, they analyzed
epidermal growth factor receptor (EGFR) protein expression by im-
munohistochemistry (IHC) and EGFR gene copy number by chro-
mogenic in situ hybridization (CISH). Twenty-four tumors were
evaluated for EGFR expression by IHC and nine were deemed highly
positive (3) forEGFR.High-level EGFRexpressionwas significantly
associated with disease control (response  stable disease) in six of
these nine cases. In contrast, analysis of EGFR copy number was
performed only on 16 available tumors, of which four exhibited high
EGFR expression. Two of these tumors, bothwith high EGFR expres-
sion, were deemedCISH positive andwere eventually associated with
a partial response in one of the two cases. The authors concluded that
assessment of EGFR level of expression by IHC predicts outcome to
gefitinib therapy more effectively than EGFR copy number by CISH.
Despite the small patient cohort, this study, however, does raise a few
points whichmay help to interpret the lack of predictive value yielded
by CISH and as such warrant further discussion.
The report byHanawaet al,2 quotedby Janmaat et al,1 found that
17 of 18 high-level EGFR expressing tumors had either EGFR ampli-
fication or low level amplification/polysomy by fluorescent in situ
hybridization, thus suggesting that an increased number of gene cop-
ies influences the high protein expression in 94%of cases. This figure,
among tumors with strong EGFR expression, is much higher than the
prevalence that Janmaatet al1 reported in their study(50%),althoughthe
cut offs adopted in both studies to score EGFR by in situ hybridization
were similar. By mere extrapolation, this discrepancy still persists when
analysis ofEGFR copynumber is extended to 1 and2EGFR staining
tumors, questioning the prevalence of increased EGFR copy number in
esophageal cancer, and the relationshipwith protein expression.
In several cancer types, a correlation between increasing levels of
EGFR protein expression by IHC and increased gene copy number
suggests that theaddictive effectof geneamplificationor chromosome
polysomy is a relevant mechanism underlying protein expression.
Remarkably, using serial sections, it has been demonstrated that re-
gions with EGFR amplification in esophageal cancer coincided with
those exhibiting 2 or 3 degrees of immunoreactivity by IHC.2 In
particular, neoplastic cells showing such immunohistochemical fea-
tures were found to constitute between 10% and 90% of the total
cells.2 Consistent with previous investigations,3 these findings imply
that the proportion of tumor cells displaying EGFR gene increased
copy number may also vary across a tumor according to the area and
the section being analyzed. As a result, the significant heterogeneity
inherent to EGFR genetic alterations could contribute to foci with
EGFR increased copy number being overlooked, and might provide
an explanation for the low prevalence of tumors with EGFR increased
copy number reported by Janmaat et al1 in their study. Furthermore,
these observations might explain the disagreement between the re-
ported rates of strong EGFR protein expression and the rates of in-
creased gene copy number, especially if assays were not performed on
serial sections, as could be the case in this study. This also raises the
possibility that the results obtained from tumor cross section analysis
may not be representative of the whole tumor.
Though several studies evaluated EGFR gene status by fluores-
cent in situ hybridization or CISH in a variety of tumors, there are no
definitive recommendations on how to proceed with EGFR scoring.
Given the real and perceived heterogeneity of EGFR distribution in
tumor sections, a scorebasedon themeannumberofEGFR copiesper
cell or the mean ratio of gene to chromosome copy, as it is currently
recommendedwithrespect toevaluationofHER2genestatus inbreast
cancer,4 still requires thorough validation. Conversely, an approach
based on the percentage of cells displaying specific patterns of EGFR
and chromosome 7 copy numbers has proven useful in segregating
subgroups of non–small-cell lung cancer patients with different out-
comes after gefitinib therapy.5,6 This kind of approach might hold
promise also in evaluating response prediction to tyrosine kinase
inhibitors through EGFR gene and protein assessments within heter-
ogeneous cancers, such as esophageal cancer. Unless investigators
validate their methodology taking into account intratumoral genetic
heterogeneity, andunless the studies are conductedon largecohortsof
patients, a problem might present itself in evaluating EGFR copy
number with in situ hybridization techniques.
Nicola Personeni
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